FAS promoter polymorphism: Outcome of childhood acute myeloid leukemia. A children's oncology group report

Clinical Cancer Research

Volumn 14, Issue 23, 2008, Pages 7896-7899

  Mehta, Parinda A ^a   Gerbing, Robert B ^c   Alonzo, Todd A ^b   Elliott, James S ^a   Zamzow, Tiffanya ^a   Combs, Michelle ^a   Stover, Emily ^a   Ross, Julie A ^d   Perentesis, John P ^a   Meschinchi, Soheil ^e   Lange, Beverlyj ^f   Davies, Stella M ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c CHILDREN S ONCOLOGY GROUP   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

^e Fred Hutchinson Cancer Research Center   (United States)

^f CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; ETOPOSIDE; FAS ANTIGEN; IDARUBICIN; INTERLEUKIN 2; TIOGUANINE; ANTINEOPLASTIC AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; APOPTOSIS; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER MORTALITY; CANCER RELAPSE; CANCER SURVIVAL; CHILD; CHILDHOOD CANCER; CONTROLLED STUDY; DRUG MEGADOSE; EVENT FREE SURVIVAL; FEMALE; GENE EXPRESSION; GENOTYPE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; NEWBORN; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; DRUG RESISTANCE; GENETICS; KAPLAN MEIER METHOD; MORTALITY; MULTIMODALITY CANCER THERAPY; PHASE 3 CLINICAL TRIAL; PILOT STUDY; PROMOTER REGION; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; ANTIGENS, CD95; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW TRANSPLANTATION; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS, PHASE III AS TOPIC; COMBINED MODALITY THERAPY; DRUG RESISTANCE, NEOPLASM; GENOTYPE; HUMANS; INFANT; INFANT, NEWBORN; KAPLAN-MEIERS ESTIMATE; LEUKEMIA, MYELOID, ACUTE; PILOT PROJECTS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 59449084600     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0418     Document Type: Article

References (22)

1. Itoh N, Yonehara S, Ishii A, et al. The polypeptide encoded bythe cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 1991;66: 233-43.
2. Oehm A, Behrmann I, Falk W, et al. PH Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor family. J Biol Chem 1992; 267:10709-15.
3. Itoh N, Nagata S. A novel protein domain required for apoptosis. Mutational analysis of human Fas antigen. J Biol Chem 1993;268:10932-7.
4. Muschen M,Warskulat U, Beckmann MW. Defining CD95 as a tumor suppressor gene. J Mol Med 2000; 78:312-25.
5. Yonehara S, Ishii A, Yonehara M. A cell-killing monoclonal antibody(anti-Fas) to a cell surface antigen co- downregulated with the receptor of tumor necrosis factor. J Exp Med 1989;169:1747-56.
6. Rieux-Laucat F, Le Deist F, Hivroz C,et al. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science 1995;268: 1347-9.
7. Davidson WF, Giese T, Fredrickson TN. Spontaneous developmentofplasmacytoid tumorsin micewith defective FAS-FAS ligand interactions. J Exp Med 1998; 187:1825-8.
8. Peters AM, Kohfink B, Martin H, et al. Defective apoptosis due to a point mutation in the death domain of CD95 associated with autoimmune lymphoproli-ferative syndrome, T-cell lymphoma, and Hodgkin's disease. Exp Hematol 1999;27:868-74.
9. Lee SH, Shin MS, Park WS, et al. Alterations of FAS (Apo-1/CD95) gene in transitional cell carcinomas of urinarybladder. Cancer Res 1999;59:3068-72.
10. Takahashi T, Tanaka M, Brannan CI, et al. Generalized lymphoproliferative disease in mice, caused bya point mutation in the FAS ligand. Cell 1994; 76:969-76.
11. SibleyK, Rollinson S, Allan JM, et al. Functional FAS promoter polymorphisms are associated with increased risk of acute myeloid leukemia. Cancer Res 2003;63:4327-30.
12. Tourneur L, Delluc S, LevyV, et al. Absence or low expression of Fas-associated protein with death domain in acute myeloid leukemia cells predicts resistance to chemotherapyand poor outcome. Cancer Res 2004;64:8101-8.
13. Lange BJ, Gerbing RB, Feusner J, et al. Mortality in over weight and underweight children with acute myeloid leukemia. JAMA 2005;293:203-11.
14. Lange BJ, Dinndorf P, Smith FO, et al. Pilot studyof idarubicin-based intensive timing induction therapy for children with previouslyuntreated acute myeloid leukemia: Children's Cancer Group (CCG) Study 2941.J Clin Oncol2004;22:150-6.
15. Mann HB, WhitneyDR. On a test of whether one of two random variables is stochastically larger than the other. Ann Math Stat 1947;18:50-60.
16. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53: 457-81.
17. Greenwood M The natural duration of cancer: reports on public health and medical subjects. London (UK): Her Majesty's Stationery Office; 1926.1:33.
18. Peto R, Peto J. Asymptotically efficient rank in variant text procedures. J R Stat Soc 1972;135:185-206.
19. GrayRJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988;16:1141 -54.
20. Traver D, Akashi K, Weissman IL, Lagasse E. Mice defective in two apoptosis pathways in the myeloid lineage develop acute myeloblastic leukemia. Immunity1998;9:47-57.
21. Delia D, Aiello A, Soligo D, et al. bcl-2 proto-onco-gene expression in normal and neoplastic human myeloid cells. Blood 1992;79:1291 -8.
22. Komada Y, Zhou YW, Zhang XL, et al. FAS receptor (CD95)-mediated apoptosis is induced in leukemic cells entering G1B compartment of the cell cycle. Blood 1995;86:3848-60.